+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Atrial Fibrillation Drug"

Atrial Fibrillation - Pipeline Insight, 2024 - Product Thumbnail Image

Atrial Fibrillation - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 60 Pages
  • Global
From
From
From
Atrial Fibrillation - Epidemiology Forecast to 2032 - Product Thumbnail Image

Atrial Fibrillation - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Atrial Fibrillation - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Atrial Fibrillation - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 929 Pages
  • Global
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Atrial Fibrillation (AF) is a type of arrhythmia, or irregular heartbeat, that affects the upper chambers of the heart. AF is a common condition, and is the most common type of arrhythmia. AF can cause a variety of symptoms, including palpitations, shortness of breath, and fatigue. Treatment for AF typically involves medications to control the heart rate and rhythm, as well as lifestyle modifications. The Atrial Fibrillation Drug market is a subset of the larger Cardiovascular Drugs market. AF drugs are used to control the heart rate and rhythm, and to reduce the risk of stroke. These drugs are typically anticoagulants, antiarrhythmics, and beta-blockers. AF drugs are used to treat both paroxysmal and persistent AF, and are often used in combination with other treatments. Some companies in the Atrial Fibrillation Drug market include Bristol-Myers Squibb, Pfizer, Sanofi, and Boehringer Ingelheim. Show Less Read more